Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

BCL2 genotypes and prostate cancer survival.

Renner W, Langsenlehner U, Krenn-Pilko S, Eder P, Langsenlehner T.

Strahlenther Onkol. 2017 Jun;193(6):466-471. doi: 10.1007/s00066-017-1126-9. Epub 2017 Apr 10.

2.

An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients.

Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Breast. 2015 Oct;24(5):667-72. doi: 10.1016/j.breast.2015.08.003. Epub 2015 Sep 4.

PMID:
26346586
3.

The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients.

Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Tumour Biol. 2016 Jan;37(1):361-8. doi: 10.1007/s13277-015-3805-4. Epub 2015 Jul 29.

PMID:
26219894
4.

Vitamin D and prostate cancer prognosis: a Mendelian randomization study.

Trummer O, Langsenlehner U, Krenn-Pilko S, Pieber TR, Obermayer-Pietsch B, Gerger A, Renner W, Langsenlehner T.

World J Urol. 2016 Apr;34(4):607-11. doi: 10.1007/s00345-015-1646-9. Epub 2015 Jul 25.

PMID:
26209090
5.

Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy.

Langsenlehner T, Pichler M, Thurner EM, Krenn-Pilko S, Stojakovic T, Gerger A, Langsenlehner U.

Urol Oncol. 2015 May;33(5):201.e9-16. doi: 10.1016/j.urolonc.2015.02.002. Epub 2015 Mar 11.

PMID:
25769845
6.

The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Eur J Cancer. 2015 Mar;51(5):610-9. doi: 10.1016/j.ejca.2015.01.002. Epub 2015 Jan 21.

PMID:
25618827
7.

Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.

Langsenlehner T, Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Gerger A, Pichler M.

World J Urol. 2015 Nov;33(11):1661-7. doi: 10.1007/s00345-015-1494-7. Epub 2015 Jan 24.

PMID:
25617235
8.

The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

World J Urol. 2015 Oct;33(10):1467-73. doi: 10.1007/s00345-014-1459-2. Epub 2014 Dec 5.

PMID:
25475065
9.

Association of vascular endothelial growth factor--a gene polymorphisms and haplotypes with breast cancer metastases.

Langsenlehner U, Hofmann G, Renner W, Gerger A, Krenn-Pilko S, Thurner EM, Krippl P, Langsenlehner T.

Acta Oncol. 2015 Mar;54(3):368-76. doi: 10.3109/0284186X.2014.948056. Epub 2014 Aug 25.

PMID:
25152223
10.

The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients.

Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T.

Br J Cancer. 2014 May 13;110(10):2524-30. doi: 10.1038/bjc.2014.163. Epub 2014 Mar 27.

11.

Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy.

Langsenlehner T, Thurner EM, Renner W, Gerger A, Kapp KS, Langsenlehner U.

Strahlenther Onkol. 2014 Apr;190(4):364-9. doi: 10.1007/s00066-013-0503-2. Epub 2014 Jan 18.

PMID:
24435801
12.

Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Renner W, Gerger A, Kapp KS, Langsenlehner T.

Strahlenther Onkol. 2014 Mar;190(3):304-9. doi: 10.1007/s00066-013-0485-0. Epub 2014 Jan 16.

PMID:
24424626
13.

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.

14.

A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer.

Absenger G, Szkandera J, Stotz M, Pichler M, Winder T, Langsenlehner T, Langsenlehner U, Samonigg H, Renner W, Gerger A.

Mol Carcinog. 2013 Nov;52 Suppl 1:E96-102. doi: 10.1002/mc.22028. Epub 2013 Apr 26.

PMID:
23625573
15.

Genetic prediction of radiation-induced morbidity in prostate cancer patients.

Langsenlehner T, Thurner EM, Krenn-Pilko S, Gerger A, Langsenlehner U.

Radiother Oncol. 2012 Dec;105(3):380-1. doi: 10.1016/j.radonc.2012.07.009. Epub 2012 Aug 18. No abstract available.

PMID:
22906548
16.

Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients.

Langsenlehner T, Renner W, Gerger A, Hofmann G, Thurner EM, Kapp KS, Langsenlehner U.

Strahlenther Onkol. 2011 Dec;187(12):784-91. doi: 10.1007/s00066-011-1106-4. Epub 2011 Nov 17.

PMID:
22105769
17.

Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.

Parmar S, Stingl JC, Huber-Wechselberger A, Kainz A, Renner W, Langsenlehner U, Krippl P, Brockmöller J, Haschke-Becher E.

Breast Cancer Res. 2011 Jun 9;13(3):R57. doi: 10.1186/bcr2894.

18.

Single nucleotide polymorphisms of integrin alpha-2 and beta-3 genes are not associated with relapse-free and overall survival in colorectal cancer patients.

Hofmann G, Langsenlehner U, Langsenlehner T, Glehr M, Gerger A, Absenger G, Szkandera J, Fuerst F, Samonigg H, Krippl P, Renner W.

Anticancer Res. 2011 Apr;31(4):1373-7.

PMID:
21508388
19.

Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.

Langsenlehner T, Renner W, Gerger A, Hofmann G, Thurner EM, Kapp KS, Langsenlehner U.

Radiother Oncol. 2011 Mar;98(3):387-93. doi: 10.1016/j.radonc.2011.01.021. Epub 2011 Feb 21.

PMID:
21345510
20.

Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.

Stingl JC, Parmar S, Huber-Wechselberger A, Kainz A, Renner W, Seeringer A, Brockmöller J, Langsenlehner U, Krippl P, Haschke-Becher E.

Curr Med Res Opin. 2010 Nov;26(11):2535-42. doi: 10.1185/03007995.2010.518304. Epub 2010 Sep 17.

PMID:
20849243
21.

Association of hypoxia-inducible factor 1-alpha gene polymorphisms and colorectal cancer prognosis.

Szkandera J, Knechtel G, Stotz M, Hofmann G, Langsenlehner U, Krippl P, Langsenlehner T, Dehchamani D, Samonigg H, Renner W, Gerger A.

Anticancer Res. 2010 Jun;30(6):2393-7.

PMID:
20651398
22.

Single nucleotide polymorphisms in the hypoxia-inducible factor-1 gene and colorectal cancer risk.

Knechtel G, Szkandera J, Stotz M, Hofmann G, Langsenlehner U, Krippl P, Samonigg H, Renner W, Langner C, Dehchamani D, Gerger A.

Mol Carcinog. 2010 Sep;49(9):805-9. doi: 10.1002/mc.20655.

PMID:
20572162
23.

Treatment results of radiation therapy for muscle-invasive bladder cancer.

Langsenlehner T, Döller C, Quehenberger F, Stranzl-Lawatsch H, Langsenlehner U, Pummer K, Kapp KS.

Strahlenther Onkol. 2010 Apr;186(4):203-9. doi: 10.1007/s00066-010-2053-1. Epub 2010 Mar 26.

PMID:
20354664
24.

Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.

Knechtel G, Hofmann G, Gerger A, Renner W, Langsenlehner T, Szkandera J, Wolf G, Samonigg H, Krippl P, Langsenlehner U.

J Cancer Res Clin Oncol. 2010 Dec;136(12):1813-9. doi: 10.1007/s00432-010-0839-2. Epub 2010 Mar 5.

PMID:
20204402
25.

The functional promoter polymorphism of the coagulation factor XII gene is not associated with peripheral arterial disease.

Yazdani-Biuki B, Krippl P, Brickmann K, Fuerst F, Langsenlehner U, Paulweber B, Pilger E, Wascher TC, Brezinschek HP, Renner W.

Angiology. 2010 Feb;61(2):211-5. doi: 10.1177/0003319709337305. Epub 2009 Jul 21.

PMID:
19625260
26.

Association of interleukin-10 gene variation with breast cancer prognosis.

Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P, Langsenlehner U.

Breast Cancer Res Treat. 2010 Feb;119(3):701-5. doi: 10.1007/s10549-009-0417-y. Epub 2009 May 13.

PMID:
19437115
27.

A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival.

Hofmann G, Langsenlehner U, Langsenlehner T, Yazdani-Biuki B, Clar H, Gerger A, Fuerst F, Samonigg H, Krippl P, Renner W.

J Cell Mol Med. 2009 Sep;13(9B):3699-702. doi: 10.1111/j.1582-4934.2009.00720.x. Epub 2009 Feb 27.

28.

Diagnostic image analysis of malignant melanoma in in vivo confocal laser-scanning microscopy: a preliminary study.

Gerger A, Wiltgen M, Langsenlehner U, Richtig E, Horn M, Weger W, Ahlgrimm-Siess V, Hofmann-Wellenhof R, Samonigg H, Smolle J.

Skin Res Technol. 2008 Aug;14(3):359-63. doi: 10.1111/j.1600-0846.2008.00303.x.

PMID:
19159384
29.

The role of radiation therapy after incomplete resection of penile cancer.

Langsenlehner T, Mayer R, Quehenberger F, Prettenhofer U, Langsenlehner U, Pummer K, Kapp KS.

Strahlenther Onkol. 2008 Jul;184(7):359-63. doi: 10.1007/s00066-008-1818-2. Epub 2008 Oct 1.

PMID:
19016034
30.

Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk.

Gerger A, Hofmann G, Langsenlehner U, Renner W, Weitzer W, Wehrschütz M, Wascher T, Samonigg H, Krippl P.

Int J Colorectal Dis. 2009 Feb;24(2):159-63. doi: 10.1007/s00384-008-0587-9. Epub 2008 Oct 3.

PMID:
18836731
31.

The Glu228Ala polymorphism in the ligand-binding domain of death receptor 4 is not associated with rheumatoid arthritis.

Yazdani-Biuki B, Brickmann K, Langsenlehner U, Renner W, Truschnig M, Krippl P, Fürst F, Graninger WB, Brezinschek HP.

Ann Rheum Dis. 2008 Jul;67(7):1053-4. doi: 10.1136/ard.2007.086124. No abstract available.

PMID:
18556450
32.

TGFB1 single-nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. In regard to Peters et al. (Int J Radiat Oncol Biol Phys 2008;70:752-759).

Langsenlehner T, Kapp KS, Langsenlehner U.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):960; author reply 960-1. doi: 10.1016/j.ijrobp.2008.02.029. No abstract available.

PMID:
18514790
33.

Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer.

Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, Kapp KS.

Eur J Cancer. 2008 Jul;44(11):1572-6. doi: 10.1016/j.ejca.2008.04.021. Epub 2008 May 29.

PMID:
18514506
34.

In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour images.

Gerger A, Hofmann-Wellenhof R, Langsenlehner U, Richtig E, Koller S, Weger W, Ahlgrimm-Siess V, Horn M, Samonigg H, Smolle J.

Br J Dermatol. 2008 Feb;158(2):329-33. doi: 10.1111/j.1365-2133.2007.08389.x.

PMID:
18215250
35.

Association of polymorphisms of angiogenesis genes with breast cancer.

Clar H, Krippl P, Renner W, Langsenlehner T, Clar V, Windhager R, Langsenlehner U.

Breast Cancer Res Treat. 2009 Jan;113(1):197-8. doi: 10.1007/s10549-008-9902-y. Epub 2008 Jan 22. No abstract available.

PMID:
18210198
36.

The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.

Langsenlehner T, Langsenlehner U, Renner W, Kapp KS, Krippl P, Hofmann G, Clar H, Pummer K, Mayer R.

Prostate. 2008 Feb 15;68(3):264-8. doi: 10.1002/pros.20682.

PMID:
18163425
37.

The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer.

Clar H, Renner W, Krippl P, Leithner A, Gruber G, Langsenlehner T, Hofmann G, Yazdani-Biuki B, Clar V, Windhager R, Langsenlehner U.

Breast Cancer Res Treat. 2008 Nov;112(2):363-5. Epub 2007 Dec 15. No abstract available.

PMID:
18080747
38.

A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients.

Clar H, Langsenlehner U, Krippl P, Renner W, Leithner A, Gruber G, Hofmann G, Yazdani-Biuki B, Langsenlehner T, Windhager R.

Breast Cancer Res Treat. 2008 Oct;111(3):449-52. Epub 2007 Nov 4.

PMID:
17978878
39.

Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk.

Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, Clar H, Gerger A, Wehrschuetz M, Samonigg H, Krippl P.

J Cancer Res Clin Oncol. 2008 May;134(5):591-5. Epub 2007 Oct 16.

PMID:
17938959
40.

Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study.

Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, Wascher TC, Paulweber B, Samonigg H, Krippl P, Renner W.

Breast Cancer Res Treat. 2008 May;109(2):297-304. Epub 2007 Jul 17.

PMID:
17636397
41.

Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome.

Langsenlehner T, Stiegler C, Quehenberger F, Feigl GC, Jakse G, Mokry M, Langsenlehner U, Kapp KS, Mayer R.

Strahlenther Onkol. 2007 May;183(5):241-7.

PMID:
17497095
42.

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis.

Langsenlehner T, Renner W, Yazdani-Biuki B, Langsenlehner U.

Breast Cancer Res Treat. 2008 Feb;107(3):459-60. Epub 2007 Apr 24.

PMID:
17453338
43.

The use of confocal laser-scanning microscopy in microsurgery for invasive squamous cell carcinoma.

Horn M, Gerger A, Koller S, Weger W, Langsenlehner U, Krippl P, Kerl H, Samonigg H, Smolle J.

Br J Dermatol. 2007 Jan;156(1):81-4.

PMID:
17199571
44.

Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study.

Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC, Pummer K, Kapp KS.

Eur J Cancer. 2007 Feb;43(3):472-5. Epub 2006 Dec 19.

PMID:
17182240
45.

A multigenic approach to predict breast cancer risk.

Gerger A, Langsenlehner U, Renner W, Weitzer W, Eder T, Yazdani-Biuki B, Hofmann G, Samonigg H, Krippl P.

Breast Cancer Res Treat. 2007 Aug;104(2):159-64. Epub 2006 Oct 21.

PMID:
17058024
46.

COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic for molecular markers.

Langsenlehner U, Gerger A, Weitzer W, Krippl P.

Breast Cancer Res Treat. 2007 Jan;101(2):247. Epub 2006 Jul 13. No abstract available.

PMID:
16838111
47.

The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients.

Yazdani-Biuki B, Brickmann K, Wohlfahrt K, Mueller T, März W, Renner W, Gutjahr M, Langsenlehner U, Krippl P, Wascher TC, Paulweber B, Graninger W, Brezinschek HP.

Arthritis Res Ther. 2006;8(4):R97.

48.

The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk.

Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P.

Clin Cancer Res. 2006 Feb 15;12(4):1392-4.

49.

Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk.

Langsenlehner U, Renner W, Yazdani-Biuki B, Eder T, Wascher TC, Paulweber B, Clar H, Hofmann G, Samonigg H, Krippl P.

Breast Cancer Res Treat. 2006 May;97(1):67-72.

PMID:
16317580
50.

Cyclin D1 genotype and breast cancer metastasis.

Langsenlehner U, Hofmann G, Samonigg H, Krippl P, Renner W, Clar H.

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1844-5. No abstract available.

Supplemental Content

Loading ...
Support Center